Search research articles
Contact Us
Filters
Showing results (1-10 of 41) with videos related to
Page
of 5
Sort By:
Idrugs : the Investigational Drugs Journal
|
June 6, 2006
Medicinal chemistry approaches to target the kinase activity of IGF-1R
Carlos Garcia-Echeverria
Journal of Medicinal Chemistry
|
September 16, 2014
Developing second generation antibody-drug conjugates: the quest for new technologies
Carlos Garcia-Echeverria
Biochemical Society Transactions
|
March 25, 2011
Blocking the mTOR pathway: a drug discovery perspective
Carlos Garcia-Echeverria
Journal of Medicinal Chemistry
|
September 5, 2013
The drug annotations series
Jeff Zablocki, Carlos Garcia-Echeverria
Bioorganic & Medicinal Chemistry Letters
|
April 2, 2013
Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic
Jean-Christophe Carry, Carlos Garcia-Echeverria
Bioorganic & Medicinal Chemistry Letters
|
April 26, 2020
Monovalent protein-degraders - Insights and future perspectives
Ivan Cornella-Taracido, Carlos Garcia-Echeverria
Bioorganic & Medicinal Chemistry Letters
|
December 3, 2014
Antibody-drug conjugates—a new wave of cancer drugs
Hervé Bouchard, Christian Viskov, Carlos Garcia-Echeverria
Current Opinion in Drug Discovery & Development
|
March 6, 2010
Hsp90 inhibitors: clinical development and future opportunities in oncology therapy
Zhenhai Gao, Carlos Garcia-Echeverria, Michael Rugaard Jensen
Expert Opinion on Therapeutic Targets
|
January 23, 2008
Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery
Sauveur-Michel Maira, Charles Voliva, Carlos Garcia-Echeverria
Current Topics in Microbiology and Immunology
|
June 29, 2010
From the bench to the bed side: PI3K pathway inhibitors in clinical development
Saveur-Michel Maira, Peter Finan, Carlos Garcia-Echeverria
Page
of 5
Search research articles
Search
Showing results (1-10 of 41) with videos related to
Sort By:
Page
of 5
Idrugs : the Investigational Drugs Journal
|
June 6, 2006
Medicinal chemistry approaches to target the kinase activity of IGF-1R
Carlos Garcia-Echeverria
Journal of Medicinal Chemistry
|
September 16, 2014
Developing second generation antibody-drug conjugates: the quest for new technologies
Carlos Garcia-Echeverria
Biochemical Society Transactions
|
March 25, 2011
Blocking the mTOR pathway: a drug discovery perspective
Carlos Garcia-Echeverria
Journal of Medicinal Chemistry
|
September 5, 2013
The drug annotations series
Jeff Zablocki, Carlos Garcia-Echeverria
Bioorganic & Medicinal Chemistry Letters
|
April 2, 2013
Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic
Jean-Christophe Carry, Carlos Garcia-Echeverria
Bioorganic & Medicinal Chemistry Letters
|
April 26, 2020
Monovalent protein-degraders - Insights and future perspectives
Ivan Cornella-Taracido, Carlos Garcia-Echeverria
Bioorganic & Medicinal Chemistry Letters
|
December 3, 2014
Antibody-drug conjugates—a new wave of cancer drugs
Hervé Bouchard, Christian Viskov, Carlos Garcia-Echeverria
Current Opinion in Drug Discovery & Development
|
March 6, 2010
Hsp90 inhibitors: clinical development and future opportunities in oncology therapy
Zhenhai Gao, Carlos Garcia-Echeverria, Michael Rugaard Jensen
Expert Opinion on Therapeutic Targets
|
January 23, 2008
Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery
Sauveur-Michel Maira, Charles Voliva, Carlos Garcia-Echeverria
Current Topics in Microbiology and Immunology
|
June 29, 2010
From the bench to the bed side: PI3K pathway inhibitors in clinical development
Saveur-Michel Maira, Peter Finan, Carlos Garcia-Echeverria
Page
of 5